Through the integration of computational biology, machine learning, and experimental validation, it not only provides a novel molecular target (GBP2) for the precise diagnosis and treatment of LN, but also successfully transforms QS from an empirical traditional Chinese medicine into a source of novel immunomodulators with validated targets, and reveals the development value of cichoriin as a natural small-molecule drug. Here, GBP2 is linked to lobular neoplasia.